Brief: Epigenomics H1 Net Loss Of EUR 7.4 Mln

Epigenomics AG

07/08/2019 07:02

Aug 7 (Reuters) - EPIGENOMICS AG  ECXn.DE :
    * IN FIRST HALF OF 2019, PRODUCT REVENUE INCREASED BY 84%
YEAR-ON-YEAR TO EUR 660 THOUSAND.
    * H1 LICENSE REVENUE DECREASED TO EUR 19 THOUSAND (6M 2018:
EUR
413 THOUSAND)
    * TOTAL REVENUE IN FIRST SIX MONTHS OF 2019 DECREASED FROM
EUR 771
THOUSAND TO EUR 679 THOUSAND
    * H1 ADJUSTED EBITDA (BEFORE SHARE-BASED PAYMENT EXPENSES)
WAS EUR
-7.2 MILLION VERSUS EUR -5.4 MILLION FOR SAME PERIOD PRIOR YEAR
    * OUTLOOK 2019: REVENUE FORECAST ADJUSTED
    * H1 NET LOSS WAS EUR -7.4 MILLION VERSUS. EUR -5.8 MILLION
FOR
PRIOR YEAR
    * OUTLOOK 2019: ADJUSTED EBITDA WITHIN RANGE OF EUR -12.5
MILLION
TO EUR -14.0 MILLION
    * OUTLOOK 2019: REVENUE FORECAST ADJUSTED FROM BETWEEN EUR
3.0
MILLION AND EUR 6.0 MILLION TO BETWEEN EUR 2.0 MILLION AND EUR
4.0 MILLION
    * OUTLOOK 2019: CASH CONSUMPTION IS EXPECTED TO BE WITHIN A
RANGE
OF EUR -13.5 MILLION TO EUR -15.0 MILLION

Source text for Eikon:  ID:nEQ7m6T0da 
Further company coverage:  ECXn.DE 

 (Gdynia Newsroom)
 ((gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))